Advances in Cancer Immunotherapy™ (ACI™-NC)

Purpose

Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs will provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs will facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.

Attendees can also take advantage of the opportunity for professional networking that will promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.

Intended Audience

The target audience for these programs includes clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics

Adoptive T Cell Therapy with Variations
Antigen Presentation
CTLA-4 Blockade: Indications and Clinical Management
Cytokines (IL-2 and IFN): Indications and Clinical Management
Immune Effector Mechanisms: B and T Cell Immunology
Modulation of the Immune Response
PD-1 Inhibition
Principles of Immunotherapy
Vaccines

Educational Objectives

Upon completion of this program, the participants will be able to:

-Interpret the key principles of tumor immunology and immunotherapy
-Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
-Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
-Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy


+ show speakers and program
Program Schedule

(as of July 11, 2014)

Presentations include allotted time for Audience Response System (ARS) assisted audience
interaction as well as general question and answer time.

8:00 am - 8:10 am Welcome and Overview

Session I: Basic Principles of Tumor Immunology and Immunotherapy with AMA PRA Category 1 Credits™

8:10 am - 8:40 am Immune Effector Mechanisms: B and T Cell Immunology

8:40 am - 9:10 am Antigen Presentation

9:10 am - 9:40 am Modulation of the Immune Response
Brent A. Hanks, MD, PhD – Duke University Medical Center

9:40 am - 10:10 am Principles of Immunotherapy
H. Kim Lyerly, MD – Duke University Medical Center

10:10 am - 10:20 am Panel Discussion

10:20 am - 10:35 am Break

Session II: Checkpoint Blockade-Based Immunotherapy with AMA PRA Category 1 Credits™

10:35 am - 11:15 am PD-1 Inhibition
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC

11:15 am - 11:55 am CTLA-4 Blockade: Indications and Clinical Management
Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center

11:55 am - 12:30 pm Panel Discussion

12:30 pm - 1:15 pm Lunch

Session III: Non-Checkpoint Blockade-Based Immunotherapy with AMA PRA Category 1 Credits™

1:15 pm - 1:45 pm Cytokines (IL-2 and IFN): Indications and Clinical Management
Richard L. White, Jr., MD, FACS – Carolinas Medical Center

1:45 pm - 2:15 pm Adoptive T Cell Therapy with Variations
Rodabe N. Amaria, MD – University of Texas, MD Anderson Cancer Center

2:15 pm - 2:45 pm Vaccines
Michael A. Morse, MD, MHS – Duke University Medical Center

2:45 pm - 3:20 pm Panel Discussion

3:20 pm - 3:30 pm Closing Remarks

3 Oct - 3 Oct 2014
Charlotte
United States of America
meeting website